Pre-eminent Peer-Reviewed Cybercrime Conference Examines Physical Impact of Cybercrime Driven by AI Innovations -- Underwritten by a Newly Wealthy Criminal Culture
Read More- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -
- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis -
- Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors -
The creators of the sam® sustained acoustic medicine technology present its proven ability to speed recovery and soft tissue healing at the University of Louisiana basketball game, part of the company's commitment to helping athletes stay healthy.
Read MoreManagement to Host Conference Call Tuesday, March 25, 2025, at 5:30 p.m. ET
Expected to be immediately accretive
Adds $6.0 million of annual unaudited revenue and $0.8 million of annual unaudited adjusted EBITDA
#1 Service and Repair plumbing company in its market
Latest acquisition under the Kingsway Search Xcelerator platform